|
Video: What is a Stock Split?
|
|
Ovid Therapeutics is a biopharmaceutical company focus on reducing seizures and epilepsies and seizure-related neurological disorders. Co.'s pipeline has produced two epilepsy programs with potential mechanisms of action (MoA), and one epilepsy program with a potential MoA. These programs include soticlestat, which is a cholesterol 24 hydroxylase inhibitor. OV350 is a potential direct activator of the K-Cl co-transporter (KCC2) transporter, and is one among many KCC2 activator compounds in its portfolio. OV329 is a GABA aminotransferase inhibitor. Co.'s genetic research programs include OV815, which focuses on the mutations associated with KIF1A-associated neurological disorder. According to our OVID split history records, Ovid Therapeutics has had 0 splits. | |
|
Ovid Therapeutics (OVID) has 0 splits in our OVID split history database.
Looking at the OVID split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Ovid Therapeutics shares, starting with a $10,000 purchase of OVID, presented on a split-history-adjusted basis factoring in the complete OVID split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/08/2017 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$12.79 |
|
End price/share: |
$3.05 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-76.15% |
|
Average Annual Total Return: |
-18.78% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$2,385.29 |
|
Years: |
6.89 |
|
|
|
|
|